FDA approves two complement C5 drugs for myasthenia gravis; first neurologic Gaucher drug approved; anticoagulants fail to beat aspirin in ESUS

A tuning fork with clamp-on weights on its tines standing upright beside a reflex hammer.

The Food and Drug Administration (FDA) approved two drugs targeting complement C5 for acetylcholine receptor antibody-positive generalized myasthenia gravis two days apart: AstraZeneca's weekly Klygefa and Regeneron's quarterly Livsayis.

The FDA also approved venglustat, the first treatment for neurological symptoms of type 3 Gaucher disease, and intrathecal adrabetadex for infantile-onset Niemann-Pick disease type C. A meta-analysis of 13,970 patients found anticoagulation did not reduce recurrent stroke versus aspirin after embolic stroke of undetermined source.

  • FDA Nov 16, 2026
    The Food and Drug Administration (FDA) approved AstraZeneca's Klygefa (gefurulimab-gaks), a dual-binding nanobody C5 inhibitor self-injected once weekly by autoinjector, for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, the company said Nov. 16. In the 260-patient phase 3 PREVAIL trial, the treatment difference versus placebo in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score at week 26 was -1.6 points (95% CI -2.4 to -0.8, P < .0001). The label carries a boxed warning for serious meningococcal infections, and access is restricted through a Risk Evaluation and Mitigation Strategy (REMS) program, NeurologyLive reported.
  • FDA Nov 18, 2026
    Regeneron said the Food and Drug Administration approved Livsayis (cemdisiran), a complement C5-directed small interfering RNA injected every three months, for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis. In the phase 3 NIMBLE trial, Myasthenia Gravis Activities of Daily Living total score improved 4.5 points with cemdisiran versus 2.2 with placebo at week 24, a placebo-adjusted 2.3 points (P = .0005), and 76.6% versus 44.1% improved by at least 3 points (P < .001). The label carries a boxed warning for serious meningococcal infections, and the drug is available only through a restricted Risk Evaluation and Mitigation Strategy program.
  • FDA Nov 18, 2026
    The Food and Drug Administration (FDA) approved Infilbray (venglustat), an oral glucosylceramide synthase inhibitor from Genzyme, a Sanofi company, that crosses the blood-brain barrier, for neurological symptoms of type 3 Gaucher disease in adults and children weighing at least 15 kg. In a randomized, double-blind trial of 43 patients 12 and older previously stabilized on enzyme replacement therapy, those on Infilbray improved on a measure combining ataxia and cognitive assessments at week 52 compared with intravenous enzyme replacement, according to the FDA, which gave no numbers. Serious psychiatric risks, including suicidal ideation and behavior, have been reported.
    Sources: FDA, NeurologyLive
  • FDA Nov 17, 2026
    The Food and Drug Administration (FDA) approved Beren Therapeutics' Lembaz (adrabetadex), given intrathecally every two weeks, to reduce the risk of death in patients weighing at least 7 kg with Niemann-Pick disease type C whose neurological symptoms began before age 6. Across 36 treated patients from three studies and an expanded access program, median survival was 8.5 years versus 4.9 years in a matched external control group, a 55% reduction in the risk of death, according to the FDA. The drug carries a boxed warning for hearing impairment, including permanent hearing loss.
    Sources: FDA, NeurologyLive
  • Research Nov 20, 2026
    An individual participant data meta-analysis of four randomized trials with 13,970 participants, published in The Lancet Neurology, compared anticoagulants with aspirin after embolic stroke of undetermined source (ESUS). The adjusted hazard ratio for recurrent stroke was 0.94 (95% CI 0.78 to 1.14), and the authors concluded anticoagulation did not reduce the risk. Major bleeding did not differ significantly between treatments (adjusted hazard ratio 1.19, 95% CI 0.52 to 2.73), with heterogeneity across trials (I² = 79%).
  • Research Nov 17, 2026
    Biogen said the 60 mg twice-yearly dose of diranersen, an intrathecal tau-targeting antisense oligonucleotide, slowed decline on the Clinical Dementia Rating Sum of Boxes by 38% at week 96, a 1.09-point difference, up from 26% at week 76. The company-reported data, presented at the Clinical Trials on Alzheimer's Disease meeting (Nov. 16 to 19), come from the open-label extension of the 416-person phase 2 CELIA trial and compare 60 treated participants with 115 originally assigned to placebo; BMO Capital Markets analysts called that comparison imperfect, Fierce Biotech reported. The trial missed its primary dose-response end point in May.
  • Research Nov 19, 2026
    In a phase 4, randomized, placebo-controlled, double-blind trial of 692 patients published in Neurology, once-daily rimegepant reduced monthly migraine days over the 12-week double-blind phase by 1.8 days more than placebo (least squares mean difference -1.8, 97.5% CI -2.35 to -1.19, P < .0001), and every-other-day dosing by 0.6 days more (-0.6, 97.5% CI -1.22 to -0.01, P = .0220). The authors concluded both regimens were superior to placebo for preventive treatment of migraine and were well tolerated.
    Sources: Neurology, PubMed

The weekly innovation roundup for neurology, published every Sunday for the week before; every item links to its sources. Latest neurology news · All specialties

Latest news

Tagged neurology, from the daily briefing

  1. FDA rejects a Duchenne cell therapy, citing data integrity violations in its pivotal trial
  2. Individual patient meta-analysis compares anticoagulants with aspirin after embolic stroke of undetermined source
  3. Rimegepant every other day and daily both cut monthly migraine days versus placebo in a 692-patient trial

See all the latest news